- Abbott (ABT, Financial) reports robust Q1 2025 earnings with 4.0% reported sales growth and 6.9% organic growth.
- Medical Devices segment shines with a 12.6% organic growth, led by Diabetes Care.
- Full-year 2025 guidance reaffirmed with projected organic sales growth of 7.5%-8.5%.
Abbott (ABT) has announced its financial results for the first quarter of 2025, showcasing a strong performance with reported sales growth of 4.0% and organic sales growth of 6.9%. The company's GAAP diluted EPS reached $0.76, while adjusted diluted EPS was $1.09, marking double-digit growth compared to the previous year.
The quarter's results were significantly driven by the Medical Devices segment, which achieved a 12.6% organic growth. Notable within this segment was the Diabetes Care division, particularly through sales of continuous glucose monitors, which contributed $1.7 billion, reflecting an 18.3% increase on a reported basis and 21.6% organic growth.
The Diagnostics segment experienced a 7.2% decline in reported sales, largely due to a decrease in COVID-19 testing sales, which fell to $84 million from the previous year's $204 million. Excluding these, the segment saw a slight organic growth of 0.5%.
Abbott has reaffirmed its full-year 2025 guidance, projecting organic sales growth between 7.5% and 8.5%, alongside an adjusted EPS range of $5.05 to $5.25. Significant developments contributing to Abbott's growth outlook include the CE Mark approval for the Voltâ„¢ PFA System and the initiation of the TECTONIC trial for the Coronary IVL System.
Furthermore, Abbott declared a quarterly dividend of $0.59 per share, highlighting its commitment to shareholder returns, marking 53 consecutive years of dividend increases. Abbott's strategic investments in manufacturing and R&D facilities in Illinois and Texas, totaling $0.5 billion, underscore its dedication to continuous product innovation and expansion.
